COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PREVAIL-TF: Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00820599
Recruitment Status : Completed
First Posted : January 12, 2009
Results First Posted : November 2, 2020
Last Update Posted : November 2, 2020
Information provided by (Responsible Party):
Edwards Lifesciences

Brief Summary:
A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; "study valve"), its transfemoral delivery system, and crimper accessories. The trial includes a premarket confirmatory cohort to evaluate the system performance as well as a Post Market Clinical Follow-up phase involving expanded enrollment and long-term follow-up of all patients to evaluate valve performance out to 5 years.

Condition or disease Intervention/treatment Phase
Aortic Valve Stenosis Device: Sapien XT™ transcatheter heart valve and delivery system Not Applicable

Detailed Description:

Edwards Lifesciences obtained CE marking authorization for transfemoral delivery / implantation of the Edwards SAPIEN™ transcatheter heart valve (model 9000TFX) using the RetroFlex™ delivery system in August 2007 and introduced these devices for commercial distribution in the European Economic Area (EEA) in October 2007.

Clinical Sites: Up to 11 sites in Europe

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 214 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transfemoral Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (EUROPE)
Actual Study Start Date : December 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TAVR
Transaortic Valve Replacement
Device: Sapien XT™ transcatheter heart valve and delivery system

Primary Outcome Measures :
  1. Number of Deaths [ Time Frame: 30 days ]
    Number of death at 30-days from the index procedure.

Secondary Outcome Measures :
  1. Number of Participants With a Stroke [ Time Frame: 30 days from the index procedure ]
    Total number of participates with a stroke.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All candidates for this study must meet all of the following inclusion criteria:

  1. Patients must have co-morbidities such that the surgeon (Co Investigator) and interventional cardiologist (Principal Investigator) concur that the predicted risk of operative mortality is > 15% with a minimum STS Risk Calculator score of ≥ 10 and/or Logistic EuroSCORE of > 20%.
  2. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class II or greater.
  3. The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided a written informed consent that has been approved by the reviewing Ethics Committee (EC) of the respective clinical site.
  4. Subject is willing to comply with specified follow up evaluations, including possible coronary angiography and transesophageal echocardiography.
  5. The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria:

  1. Aortic valve is a congenital unicuspid or bicuspid valve, or is non-calcified.
  2. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+).
  3. Any therapeutic invasive cardiac procedure, other than BAV, performed within 30 days of the index procedure (or 6 months if the procedure was a drug eluting coronary stent implantation).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00820599

Layout table for location information
Ornze Lieve Vrouwziekenhuis (OLVZ) Aalst
Aalst, Belgium, 9300
Institut Hospitalier Jacques Cartier
Massy, France, 91300
Hospital Bichat Claude Bernard
Paris, France, 75018
CHU Hospital Charles Nicolle
Rouen, France, 76000
Clinique Pasteur
Toulouse, France, 31076
Hamburg University Cardiovascular Center
Hamburg, Germany, 22527
City Clinics Karlsruhe
Karlsruhe, Germany, 76185
Heart Center Leipzig
Leipzig, Germany, 04829
Schwabing Clinic
Munich, Germany, 80804
United Kingdom
St. Thomas' Hospital - NHS Trust
London, United Kingdom, SE1 7EH
Kings College Hospital - NHS Trust
London, United Kingdom, SE5 9RS
Sponsors and Collaborators
Edwards Lifesciences
Layout table for investigator information
Study Director: Prof. Dr. Stefan Sack Cardiology Clinic of Schwabing Clinic
Study Director: Isabelle Fourthin Edwards Lifesciences SA
Layout table for additonal information
Responsible Party: Edwards Lifesciences Identifier: NCT00820599    
Other Study ID Numbers: 2008-04
First Posted: January 12, 2009    Key Record Dates
Results First Posted: November 2, 2020
Last Update Posted: November 2, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Edwards Lifesciences:
Sapien Valve
Cardiovascular Diseases
Valvular Heart Disease
Aortic Stenosis
Heart Valve Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction